- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00269906
A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty
Chimeric Anti-Platelet Therapy (Abciximab) in Unstable Angina Refractory to Standard Medical Therapy Trial (CAPTURE)
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a randomized, placebo-controlled study to evaluate the safety and efficacy of abciximab, an anti-platelet therapy, in patients with unstable angina who are not responding to standard medical therapy and who are eligible for coronary angioplasty. The primary outcomes of the study include any of the following within 30 days: the number of deaths from any cause, myocardial infarctions or the number of recurrent ischemic events requiring urgent intervention (such as a coronary artery bypass surgery, repeat coronary angioplasty, coronary stent placement, or intra-aortic balloon pump). Please see attached results.
Patients will be treated with abciximab or matching placebo.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with refractory angina as evidenced by at least one episode of ischemia (chest pain and/or ST-T changes) despite bed rest and at least 2 hours of treatment with oral or intravenous nitrates and intravenous heparin, or persistent newly developed negative T-waves occurring or continuing after at least 2 hours of treatment with oral or intravenous nitrates and intravenous heparin
- Having clinical signs and symptoms of angina at rest or minimal exertion with dynamic ST-segment and/or T-wave changes
- Having an episode of chest pain within 48 hours prior to the start of study agent administration
- Having a culprit lesion in a single native coronary vessel suitable for angioplasty on the qualifying angiogram
Exclusion Criteria:
- Patients who have had a recent myocardial infarction, unless CK has returned to less than twice the upper limit of normal
- Having features of ongoing ischemia that would require immediate intervention, or had a percutaneous transluminal coronary angioplasty (PTCA) within the past 24 hours
- Having an unprotected occlusion of the main left coronary artery > 50%, a culprit lesion located in a venous or arterial bypass graft, or recent bleeding or a condition associated with increased bleeding risk
- Receiving concurrent administration of oral anticoagulants at the time of study entry, administration of intravenous dextran (prior to or planned for use during angioplasty), or planned administration of thrombolytic agent prior to or during angioplasty
- Having persistent hypertension at admission despite treatment, or a platelet count less than 100,000 per millimeter cubed
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Abciximab (c7E3 Fab)
Participants will receive 0.25 milligram per kilogram (mg/kg) of body weight abciximab as bolus intravenous injection followed by continuous infusion of abciximab at rate of 10 microgram per minute for at least 18 hours but not longer than 26 hours.
|
Other Names:
|
Placebo Comparator: Placebo
Participants will receive matching placebo as bolus IV injection followed by continuous infusion of matching placebo for at least 18 hours but no longer than 26 hours.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants who Died From Any Cause
Time Frame: Up to 30 Days
|
Up to 30 Days
|
Number of Participant with any one of these: Myocardial Infraction, Recurrent Ischemic Events Requiring Urgent Intervention (Coronary Artery Bypass Surgery, Repeat Coronary Angioplasty, Coronary Stent Placement, Intra-aortic Balloon Pump)
Time Frame: Up to 30 Days
|
Up to 30 Days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants With New Ischemia
Time Frame: From onset of infusion to percutaneous transluminal coronary angioplasty (PTCA), and from PTCA through 24 hours after PTCA
|
From onset of infusion to percutaneous transluminal coronary angioplasty (PTCA), and from PTCA through 24 hours after PTCA
|
Number of Participants With PTCA Complications
Time Frame: From onset of infusion to PTCA, and from PTCA through 24 hours after PTCA
|
From onset of infusion to PTCA, and from PTCA through 24 hours after PTCA
|
Number of Participants With use of Thrombolytic Agents in the Catheterization
Time Frame: Day 1
|
Day 1
|
Number of Participants With use of a Balloon Perfusion Catheter During Procedure
Time Frame: Day 1
|
Day 1
|
Number of Particpants With Late Major Clinical Events
Time Frame: From Day 30 up to 6 Months
|
From Day 30 up to 6 Months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR006271
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Angina, Unstable
-
Korea University Anam HospitalCompletedDiabetic Stable Angina | Diabetic Unstable AnginaKorea, Republic of
-
Gennaro SardellaUnknownNon ST Segment Elevation MI and Unstable AnginaItaly
-
University Hospital TuebingenAcrostakUnknownMyocardial Ischemia | Stable or Unstable Angina PectorisGermany
-
Bon-Kwon KooSamsung Medical Center; Chonnam National University Hospital; Seoul National... and other collaboratorsCompleted
-
Ulsan University HospitalSeoul National University HospitalCompletedStable Angina | Unstable AnginaKorea, Republic of
-
CID - Carbostent & Implantable DevicesCompletedStable Angina | Unstable Angina | NSTEMINetherlands, Italy
-
Ospedale San DonatoTerminatedStable Angina | Unstable AnginaItaly
-
Medhub Ltd.CompletedStable Angina | Unstable Angina | NSTEMIIsrael
-
Jun LiUnknown
-
Jun LiGuang'anmen Hospital of China Academy of Chinese Medical SciencesUnknown
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States